What is Leerink Partnrs’ Forecast for MIRM FY2024 Earnings?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Mirum Pharmaceuticals in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.60) per share for the year, up from their previous forecast of ($1.63). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals’ Q4 2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.83) EPS.

Several other brokerages have also issued reports on MIRM. Leerink Partners boosted their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Citigroup raised their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Trading Down 2.3 %

Shares of NASDAQ MIRM opened at $47.53 on Friday. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $49.27. The firm has a market capitalization of $2.28 billion, a P/E ratio of -23.53 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company’s 50 day simple moving average is $43.76 and its 200 day simple moving average is $41.53.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals’s revenue was up 89.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.57) EPS.

Insider Activity

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 7,489 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the transaction, the chief executive officer now owns 119,359 shares of the company’s stock, valued at $5,110,952.38. The trade was a 5.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jolanda Howe sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the sale, the senior vice president now directly owns 2,426 shares of the company’s stock, valued at approximately $114,264.60. The trade was a 50.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,706 shares of company stock valued at $875,697. 22.87% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Amalgamated Bank raised its holdings in Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after acquiring an additional 513 shares in the last quarter. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth $69,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares during the period. Avanza Fonder AB bought a new position in Mirum Pharmaceuticals during the 4th quarter worth approximately $189,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Mirum Pharmaceuticals during the third quarter worth $215,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.